Incheon, South Korea

Minyoung Kim


 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Minyoung Kim: Innovator in Anticancer Peptide Research

Introduction

Minyoung Kim is a prominent inventor based in Incheon, South Korea. He has made significant contributions to the field of cancer research through his innovative work on peptides with anticancer activity. His research focuses on developing effective pharmaceutical compositions and health functional foods aimed at preventing and treating cancer.

Latest Patents

Minyoung Kim holds 1 patent for his invention titled "Peptide having anticancer activity, and pharmaceutical composition, health functional food composition and functional cosmetic composition for preventing and treating cancer comprising the same as active ingredient." This patent describes a peptide that binds to the transcription factor CP2c, showcasing prophylactic and therapeutic activities against cancer. The invention includes various compositions that utilize this peptide as an active ingredient, highlighting its potential in cancer treatment.

Career Highlights

Minyoung Kim is affiliated with the Industry-University Cooperation Foundation at Hanyang University. His work at this institution has allowed him to collaborate with other researchers and contribute to advancements in medical science, particularly in the area of cancer therapeutics.

Collaborations

Minyoung Kim has worked alongside notable colleagues, including Chul Geun Kim and Chan Gil Kim. Their collaborative efforts have furthered research in the field and enhanced the impact of their findings on cancer treatment.

Conclusion

Minyoung Kim's innovative research on anticancer peptides represents a significant advancement in the fight against cancer. His contributions through patents and collaborations continue to pave the way for new therapeutic options in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…